Development of idraparinux and idrabiotaparinux for anticoagulant therapy.

@article{Harenberg2009DevelopmentOI,
  title={Development of idraparinux and idrabiotaparinux for anticoagulant therapy.},
  author={Job Harenberg},
  journal={Thrombosis and haemostasis},
  year={2009},
  volume={102 5},
  pages={811-5}
}
Idraparinux is an analogue of fondaparinux binding with high affinity to antithrombin. It was designed for weekly, rather than daily, administration, with an exceptionally long half-life. One potential problem with small heparin-like fragments of this type is the difficulty of neutralising excessive activity in the case of side-effects or overdose. The efficacy of idraparinux was was proven in clinical studies with patients suffering from venous thromboembolism (VTE) or atrial fibrillation. Due… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials

  • J Harenberg, I Jörg, Y Vukojevic
  • Eur J Clin Pharmacol
  • 2008
2 Excerpts

Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin

  • HR Buller, JM Destors, AS Gallus
  • Blood
  • 2008
2 Excerpts

Long elimination half life of idraparinux after termination of therapy explains bleeding in the van Gogh trials

  • J Harenberg, C Weiss, G Mikus
  • J Thromb Haemost 2008;
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…